| ￥3300 | |
| Z05283 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 32.8 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
FcRH6/FCRL6, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Fc receptor-like 6 (FCRL6), the most recently characterized member of the FCRL family, is a cell surface glycoprotein with tyrosine-based regulatory potential. An extensive survey of human hematopoietic tissues disclosed that FCRL6 expression by NK- and T-cell subpopulations increases as a function of differentiation and is remarkably restricted to mature lymphocytes with cytotoxic capability. |
| Synonyms | Fc receptor-like protein 6;FcR-like protein 6;Fc receptor homolog 6;IFGP6;FLJ16056 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
